Soleno Therapeutics Faces Class Action Lawsuit Deadline

Investors have until May 5, 2026 to apply for lead plaintiff status in case against pharmaceutical company.

Mar. 14, 2026 at 7:14am

Got story updates? Submit your updates here. ›

Kahn Swick & Foti, LLC, a national securities litigation law firm, has notified investors in Soleno Therapeutics, Inc. of a class action lawsuit related to alleged securities fraud between March 26, 2025 and November 4, 2025. The lawsuit claims Soleno and its executives failed to disclose material information about safety concerns with the company's only commercial product, DCCR, which is used to treat hyperphagia in individuals with Prader-Willi syndrome.

Why it matters

This case highlights the importance of pharmaceutical companies fully disclosing potential safety risks associated with their products, especially for drugs treating rare and serious conditions like Prader-Willi syndrome. Investors rely on accurate information to make informed decisions, and allegations of securities fraud can significantly impact a company's reputation and financial standing.

The details

According to the complaint, Soleno is accused of systematically minimizing, mischaracterizing, and/or failing to disclose substantial evidence of potential safety concerns with DCCR, including indications of excessive fluid retention among clinical trial participants. This allegedly made DCCR's commercial viability and the likelihood of significant adverse events after launch much riskier than disclosed.

  • The class action lawsuit covers the period from March 26, 2025 to November 4, 2025.
  • Investors have until May 5, 2026 to apply for lead plaintiff status in the case.

The players

Soleno Therapeutics, Inc.

A pharmaceutical company developing DCCR, a treatment for hyperphagia in individuals with Prader-Willi syndrome.

Kahn Swick & Foti, LLC

A national securities litigation law firm that has notified Soleno investors of the class action lawsuit.

Charles C. Foti, Jr.

A partner at Kahn Swick & Foti, LLC and former Attorney General of Louisiana.

Lewis Kahn

The managing partner at Kahn Swick & Foti, LLC.

Got photos? Submit your photos here. ›

What they’re saying

“Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.”

— Lewis Kahn, Managing Partner, Kahn Swick & Foti, LLC

What’s next

The judge will decide on May 5, 2026 whether to appoint a lead plaintiff in the class action lawsuit against Soleno Therapeutics.

The takeaway

This case highlights the importance of pharmaceutical companies being transparent about potential safety risks with their products, especially for drugs treating rare and serious conditions. Investors rely on accurate information to make informed decisions, and allegations of securities fraud can significantly impact a company's reputation and financial standing.